T4580
Tiludronate disodium salt hydrate
≥98% (HPLC)
别名:
Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C7H7ClNa2O6P2S · xH2O
CAS号:
分子量:
362.57 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推荐产品
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to off-white
溶解度
H2O: >10 mg/mL, clear
起源
Sanofi Aventis
SMILES 字串
O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O
InChI
1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2
InChI 密鑰
SZVJRJRMQCKFON-UHFFFAOYSA-L
生化／生理作用
Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.
特點和優勢
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Peter Alexandersen et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 20(4), 588-595 (2005-03-15)
A new resorption assay measuring non-isomerized collagen type I C-telopeptide fragments (alpha-alpha CTX) was evaluated in a cohort comprising 32 Pagetic patients and 48 healthy controls. alpha-alpha CTX was found to be a sensitive marker for assessing disease activity and
Katja F Duesterdieck-Zellmer et al.
American journal of veterinary research, 73(10), 1530-1539 (2012-09-28)
To determine concentration-dependent effects of tiludronate on cartilage explants incubated with or without recombinant equine interleukin-1β (rEq IL-1). Articular cartilage explants from the femorotibial joints of 3 young adult horses. Cartilage explants were incubated with 1 of 6 concentrations (0
Patricia Pascaud et al.
Langmuir : the ACS journal of surfaces and colloids, 29(7), 2224-2232 (2013-01-16)
Bisphosphonates (BPs) are well established as successful antiresorptive agents for the prevention and treatment of bone diseases such as osteoporosis and Paget's disease. The aim of this work was to clarify the reaction mechanisms between a BP molecule, tiludronate, and
Jean-Pierre Pelletier et al.
The Journal of rheumatology, 38(1), 118-128 (2010-10-19)
to investigate over a 1-year period in dogs that underwent extracapsular stabilization surgery (ECS) following anterior cruciate ligament (ACL) transection: whether reconstructive surgery could prevent osteoarthritis (OA) progression and whether treatment with the bisphosphonate tiludronic acid (TA) could improve the
Virginie Coudry et al.
American journal of veterinary research, 68(3), 329-337 (2007-03-03)
To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. 29 horses with clinical manifestations of pain associated with lesions of the thoracolumbar vertebral column and abnormal
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门